Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients

  1. Cécile Alanio
  2. Francesco Nicoli
  3. Philippe Sultanik
  4. Tobias Flecken
  5. Brieuc Perot
  6. Darragh Duffy
  7. Elisabetta Bianchi
  8. Annick Lim
  9. Emmanuel Clave
  10. Marit M van Buuren
  11. Aurélie Schnuriger
  12. Kerstin Johnsson
  13. Jeremy Boussier
  14. Antoine Garbarg-Chenon
  15. Laurence Bousquet
  16. Estelle Mottez
  17. Ton N Schumacher
  18. Antoine Toubert
  19. Victor Appay
  20. Farhad Heshmati
  21. Robert Thimme
  22. Stanislas Pol
  23. Vincent Mallet
  24. Matthew L Albert  Is a corresponding author
  1. Institut Pasteur, France
  2. University Pierre et Marie Curie, France
  3. Albert-Ludwigs-Universität, Germany
  4. Assistance publique - hôpitaux de Paris, France
  5. The Netherlands Cancer Institute, Netherlands
  6. Lunds University, Sweden
  7. Assistance publique - Hôpitaux de Paris, France
  8. Université Paris Descartes, France
  9. Assistance Publique - Hôpitaux de Paris, France
  10. Albert-Ludwigs-Universität Freiburg, Germany

Abstract

Chronic infection perturbs immune homeostasis. While prior studies have reported dysregulation of effector and memory cells, little is known about the effects on naïve T cell populations. We performed a cross-sectional study of chronic hepatitis C (cHCV) patients using tetramer-associated magnetic enrichment to study antigen-specific inexperienced CD8+ T cells (i.e., tumor or unrelated virus-specific populations in tumor-free and sero-negative individuals). cHCV showed normal precursor frequencies, but increased proportions of memory-phenotype inexperienced cells, as compared to healthy donors or cured HCV patients. These observations could be explained by low surface expression of CD5, a negative regulator of TCR signaling. Accordingly, we demonstrated TCR hyperactivation and generation of potent CD8+ T cell responses from the altered T cell repertoire of cHCV patients. In sum, we provide the first evidence that naïve CD8+ T cells are dysregulated during cHCV infection, and establish a new mechanism of immune perturbation secondary to chronic infection.

Article and author information

Author details

  1. Cécile Alanio

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Francesco Nicoli

    Centre d'Immunologie et des Maladies Infectieuses, University Pierre et Marie Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Philippe Sultanik

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Tobias Flecken

    The University Medical Center Freiburg, Department of Internal Medicine II, Albert-Ludwigs-Universität, Freiburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Brieuc Perot

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Darragh Duffy

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Elisabetta Bianchi

    Immunoregulation Unit, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Annick Lim

    Plateforme d'Immunoscope, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Emmanuel Clave

    Hôpital Saint Louis, Assistance publique - hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Marit M van Buuren

    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  11. Aurélie Schnuriger

    Laboratoire de virologie, Hôpital Armand-Trousseau, Assistance publique - hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Kerstin Johnsson

    Mathematics, Faculty of Engineering, Lunds University, Lund, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  13. Jeremy Boussier

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Antoine Garbarg-Chenon

    Laboratoire de virologie, Hôpital Armand-Trousseau, Assistance publique - Hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Laurence Bousquet

    Institut Cochin, Université Paris Descartes, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Estelle Mottez

    Centre d'Immunologie Humaine, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Ton N Schumacher

    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  18. Antoine Toubert

    Hôpital Saint-Louis, Assistance publique - hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  19. Victor Appay

    Centre d'Immunologie et des Maladies Infectieuses, University Pierre et Marie Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  20. Farhad Heshmati

    Etablissement Français du Sang, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  21. Robert Thimme

    The University Medical Center Freiburg, Department of Internal Medicine II, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  22. Stanislas Pol

    Institut Cochin, Université Paris Descartes, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  23. Vincent Mallet

    Institut Cochin, Université Paris Descartes, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  24. Matthew L Albert

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    For correspondence
    albertm@pasteur.fr
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Human subjects: 29 cHCV, 37 SVR, and 18 cHBV patients were included (Table 1). All subjects were followed in the Liver Unit of H�pital Cochin (Paris, France) or the Department of Internal Medicine II (Freiburg, Germany). French samples were obtained as part of study protocol C11-33 approved by the INSERM clinical investigation department with ethical approval from the CPP Ile-de-France II, Paris (ClinicalTrials.gov identifier: n{degree sign}NCT01534728). German samples were obtained in the University Hospital Freiburg according to regulations of local ethic committee. Both study protocols conformed to the ethical guidelines of the Declaration of Helsinki, and patients provided informed consent.

Copyright

© 2015, Alanio et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,751
    views
  • 489
    downloads
  • 46
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Cécile Alanio
  2. Francesco Nicoli
  3. Philippe Sultanik
  4. Tobias Flecken
  5. Brieuc Perot
  6. Darragh Duffy
  7. Elisabetta Bianchi
  8. Annick Lim
  9. Emmanuel Clave
  10. Marit M van Buuren
  11. Aurélie Schnuriger
  12. Kerstin Johnsson
  13. Jeremy Boussier
  14. Antoine Garbarg-Chenon
  15. Laurence Bousquet
  16. Estelle Mottez
  17. Ton N Schumacher
  18. Antoine Toubert
  19. Victor Appay
  20. Farhad Heshmati
  21. Robert Thimme
  22. Stanislas Pol
  23. Vincent Mallet
  24. Matthew L Albert
(2015)
Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients
eLife 4:e07916.
https://doi.org/10.7554/eLife.07916

Share this article

https://doi.org/10.7554/eLife.07916

Further reading

    1. Immunology and Inflammation
    Josep Garnica, Patricia Sole ... Pere Santamaria
    Research Article

    Chronic antigenic stimulation can trigger the formation of interleukin 10 (IL-10)-producing T-regulatory type 1 (TR1) cells in vivo. We have recently shown that murine T-follicular helper (TFH) cells are precursors of TR1 cells and that the TFH-to-TR1 cell transdifferentiation process is characterized by the progressive loss and acquisition of opposing transcription factor gene expression programs that evolve through at least one transitional cell stage. Here, we use a broad range of bulk and single-cell transcriptional and epigenetic tools to investigate the epigenetic underpinnings of this process. At the single-cell level, the TFH-to-TR1 cell transition is accompanied by both, downregulation of TFH cell-specific gene expression due to loss of chromatin accessibility, and upregulation of TR1 cell-specific genes linked to chromatin regions that remain accessible throughout the transdifferentiation process, with minimal generation of new open chromatin regions. By interrogating the epigenetic status of accessible TR1 genes on purified TFH and conventional T-cells, we find that most of these genes, including Il10, are already poised for expression at the TFH cell stage. Whereas these genes are closed and hypermethylated in Tconv cells, they are accessible, hypomethylated, and enriched for H3K27ac-marked and hypomethylated active enhancers in TFH cells. These enhancers are enriched for binding sites for the TFH and TR1-associated transcription factors TOX-2, IRF4, and c-MAF. Together, these data suggest that the TR1 gene expression program is genetically imprinted at the TFH cell stage.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Stephanie Guillet, Tomi Lazarov ... Frédéric Geissmann
    Research Article

    Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.